BRPI0616223A2 - combinaÇço de fÁrmacos - Google Patents

combinaÇço de fÁrmacos Download PDF

Info

Publication number
BRPI0616223A2
BRPI0616223A2 BRPI0616223-1A BRPI0616223A BRPI0616223A2 BR PI0616223 A2 BRPI0616223 A2 BR PI0616223A2 BR PI0616223 A BRPI0616223 A BR PI0616223A BR PI0616223 A2 BRPI0616223 A2 BR PI0616223A2
Authority
BR
Brazil
Prior art keywords
probucol
combination
tetrazolylalkoxy
prevention
treatment
Prior art date
Application number
BRPI0616223-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ki Whan Hong
Tomohiro Yoshikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0616223A2 publication Critical patent/BRPI0616223A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0616223-1A 2005-09-15 2006-09-14 combinaÇço de fÁrmacos BRPI0616223A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71695405P 2005-09-15 2005-09-15
US60/716,954 2005-09-15
US76177506P 2006-01-25 2006-01-25
US60/761,775 2006-01-25
PCT/JP2006/318675 WO2007032557A1 (en) 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects

Publications (1)

Publication Number Publication Date
BRPI0616223A2 true BRPI0616223A2 (pt) 2011-06-14

Family

ID=37420867

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616223-1A BRPI0616223A2 (pt) 2005-09-15 2006-09-14 combinaÇço de fÁrmacos

Country Status (20)

Country Link
US (2) US8580818B2 (enExample)
EP (2) EP2275106A1 (enExample)
JP (2) JP5179354B2 (enExample)
KR (1) KR101299320B1 (enExample)
AR (1) AR057520A1 (enExample)
AU (1) AU2006289752B2 (enExample)
BR (1) BRPI0616223A2 (enExample)
CA (1) CA2620296C (enExample)
CY (1) CY1112716T1 (enExample)
DK (1) DK1942895T3 (enExample)
ES (1) ES2378896T3 (enExample)
IL (1) IL189751A0 (enExample)
MY (1) MY145787A (enExample)
NO (1) NO20081811L (enExample)
PL (1) PL1942895T3 (enExample)
PT (1) PT1942895E (enExample)
RU (1) RU2411945C2 (enExample)
SG (1) SG165379A1 (enExample)
TW (1) TWI372053B (enExample)
WO (1) WO2007032557A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065588A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad pulmonar obstructiva cronica
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
CN120441542B (zh) * 2025-05-08 2025-09-30 安徽益普克医药科技发展有限公司 一种西洛他唑衍生物及其制备方法与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH04193836A (ja) * 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
JPH107590A (ja) 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
EP0946178A4 (en) 1996-09-18 2003-05-07 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
WO1999024400A1 (en) * 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
AU5965399A (en) 1998-10-12 2000-05-01 Andreas Bockelmann Pharmaceutically active composition
EP1272220B2 (en) 2000-04-10 2016-07-27 Nicholas John Wald Formulation for the prevention of cardiovascular disease
US20020115728A1 (en) * 2000-09-05 2002-08-22 Roland Stocker Compositions and methods for treating cardiovascular disorders
CN1582168A (zh) * 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003192573A (ja) 2001-12-25 2003-07-09 Otsuka Pharmaceut Factory Inc 経口ゲル製剤
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
US20090227610A1 (en) 2005-06-08 2009-09-10 Kowa Company, Ltd. Novel triglyceride reducing agent
JP4193836B2 (ja) 2005-10-24 2008-12-10 ブラザー工業株式会社 インク噴射装置の製造方法

Also Published As

Publication number Publication date
EP1942895B1 (en) 2012-02-01
CY1112716T1 (el) 2016-02-10
JP2009508804A (ja) 2009-03-05
RU2411945C2 (ru) 2011-02-20
KR101299320B1 (ko) 2013-09-03
JP5603393B2 (ja) 2014-10-08
US8580818B2 (en) 2013-11-12
MY145787A (en) 2012-04-30
PL1942895T3 (pl) 2012-07-31
US20140045889A1 (en) 2014-02-13
NO20081811L (no) 2008-04-14
SG165379A1 (en) 2010-10-28
CA2620296A1 (en) 2007-03-22
KR20080049822A (ko) 2008-06-04
HK1122996A1 (en) 2009-06-05
IL189751A0 (en) 2008-12-29
WO2007032557A1 (en) 2007-03-22
ES2378896T3 (es) 2012-04-18
JP5179354B2 (ja) 2013-04-10
RU2008114512A (ru) 2009-10-20
AU2006289752B2 (en) 2011-06-09
CA2620296C (en) 2013-10-22
DK1942895T3 (da) 2012-03-05
EP1942895A1 (en) 2008-07-16
EP2275106A1 (en) 2011-01-19
TW200744597A (en) 2007-12-16
JP2013014605A (ja) 2013-01-24
TWI372053B (en) 2012-09-11
AR057520A1 (es) 2007-12-05
AU2006289752A1 (en) 2007-03-22
US20090176826A1 (en) 2009-07-09
PT1942895E (pt) 2012-03-29

Similar Documents

Publication Publication Date Title
Jo et al. TRPV4 and AQP4 channels synergistically regulate cell volume and calcium homeostasis in retinal Müller glia
AU2018203357B2 (en) New methods
Weinberg et al. Anaerobic and aerobic pathways for salvage of proximal tubules from hypoxia-induced mitochondrial injury
Schreml et al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585
Clausen et al. Mechanisms of rapid reactive oxygen species generation in response to cytosolic Ca2+ or Zn2+ loads in cortical neurons
Amacher Drug-associated mitochondrial toxicity and its detection
Zhan et al. Intravenous anesthetics differentially reduce neurotransmission damage caused by oxygen-glucose deprivation in rat hippocampal slices in correlation with N-methyl-D-aspartate receptor inhibition
Fang et al. Mechanisms of star fruit-induced acute renal failure
Li et al. A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic
Zhang et al. Retracted: Activation of Akt Rescues Endoplasmic Reticulum Stress-Impaired Murine Cardiac Contractile Function via Glycogen Synthase Kinase-3β-Mediated Suppression of Mitochondrial Permeation Pore Opening
Stotz et al. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication
Harraz et al. Cocaine-induced locomotor stimulation involves autophagic degradation of the dopamine transporter
Parodi-Rullán et al. Divergent effects of cyclophilin-D inhibition on the female rat heart: Acute versus chronic post-myocardial infarction
EP3065728A1 (en) Novel methods
Jaturakan et al. Combination of vitamin E and vitamin C alleviates renal function in hyperoxaluric rats via antioxidant activity
Chu et al. β-hydroxybutyrate administered at reperfusion reduces infarct size and preserves cardiac function by improving mitochondrial function through autophagy in male mice
CN118001283A (zh) 用于预防及治疗糖尿病性肾病的包含腺苷衍生物的药学组合物
Wang et al. Endogenous H2S sensitizes PAR4-induced bladder pain
US20140045889A1 (en) Combination Drug Containing Probucol and a Tetrazolyalkoxy-Dihydrocarbostyril Derivative With Superoxide Supressant Effects
CN101267823B (zh) 具有超氧化物抑制作用的包含普罗布考和四唑基烷氧基-二氢喹诺酮衍生物的组合药物
Santos Laso Role of endoplasmic reticulum stress in the pathogenesis of polycystic liver disease: new potential therapeutic target
Tinson et al. Supporting the intoxicated veterinary patient (part 2): Toxicants affecting the neurological and cardiovascular systems.
WO2013067415A1 (en) Identification and use of protease inhibitors to treat or prevent sickle cell disease
Lo et al. Articles in PresS. Am J Physiol Endocrinol Metab (September 22, 2015). doi: 10.1152/ajpendo. 00151.2015
Kaye John 0. Bell, Geoffrey Edwards, James L. Maggs, Laurence P. Bishop, Paul M. O'Neill, Stephen A. Ward, Peter A. Winstanley and B. Kevin Park, Department of Pharmacology & Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3GE.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.